Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab
Reumatol Clin (Engl Ed). 2020 Jan-Feb;16(1):64-65.
doi: 10.1016/j.reuma.2018.01.003.
Epub 2018 Feb 19.
[Article in
English,
Spanish]
Affiliations
- 1 Universidad Militar Nueva Granada, Bogotá, Colombia; Servicio de Reumatología, Hospital Militar Central, Bogotá, Colombia. Electronic address: annychs@gmail.com.
- 2 Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá, Colombia.
- 3 Servicio de Reumatología, Hospital Militar Central, Bogotá, Colombia; Reumatólogo, Hospital Militar Central, Bogotá, Colombia.
No abstract available
MeSH terms
-
Adalimumab / therapeutic use
-
Adult
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use*
-
Female
-
Humans
-
Infliximab / therapeutic use
-
Methotrexate / therapeutic use
-
Spondylitis, Ankylosing / complications
-
Spondylitis, Ankylosing / drug therapy*
-
Sulfasalazine / therapeutic use
-
Treatment Failure
-
Tumor Necrosis Factor Inhibitors / therapeutic use*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Uveitis / drug therapy*
-
Uveitis / etiology
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Tumor Necrosis Factor Inhibitors
-
Tumor Necrosis Factor-alpha
-
Sulfasalazine
-
golimumab
-
Infliximab
-
Adalimumab
-
Methotrexate